Free Trial
NASDAQ:ALZN

Alzamend Neuro 9/11/2024 Earnings Report

Alzamend Neuro logo
$0.67 0.00 (0.00%)
As of 03:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alzamend Neuro EPS Results

Actual EPS
-$1.25
Consensus EPS
-$2.38
Beat/Miss
Beat by +$1.13
One Year Ago EPS
N/A

Alzamend Neuro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alzamend Neuro Announcement Details

Quarter
Time
TAS
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Alzamend Neuro Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

View Alzamend Neuro Profile

More Earnings Resources from MarketBeat